查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1799105

全球製藥和生物技術領域的人工智慧市場

Artificial Intelligence (AI) in Pharma and Biotech
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 142 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計到 2030 年，全球製藥和生物技術領域的人工智慧 (AI) 市場規模將達到 90 億美元

2024年，全球製藥和生物技術領域的人工智慧 (AI) 市場規模估計為31億美元，預計2024年至2030年期間的複合年成長率將達到19.2%，到2030年將達到90億美元。藥物發現和開發應用是本報告分析的細分領域之一，預計其複合年成長率將達到17.9%，到分析期結束時規模將達到26億美元。臨床試驗和最佳化應用細分領域在分析期間的複合年成長率預計將達到17.8%。

美國市場規模估計為 8.228 億美元，中國市場預計複合年成長率為 18.3%

美國製藥和生物技術領域的人工智慧 (AI) 市場規模預計在 2024 年達到 8.228 億美元。作為世界第二大經濟體，中國預計到 2030 年市場規模將達到 14 億美元，在 2024-2030 年的分析期內，複合年成長率為 18.3%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間內，這兩個市場的複合年成長率分別為 17.5% 和 16.8%。在歐洲，預計德國市場的複合年成長率約為 14.3%。

全球製藥和生物技術領域的人工智慧 (AI) 市場—主要趨勢和促進因素摘要

人工智慧將如何徹底改變藥物發現和開發生命週期？

人工智慧正在透過加速和最佳化整個藥物發現和開發過程，極大地重塑製藥和生物技術產業。傳統的藥物開發是一項昂貴且耗時的工作，通常需要十多年的時間，耗資數十億美元才能將新藥推向市場。人工智慧正在改變這種模式，它能夠快速分析大量資料集，包括基因組學、蛋白質組學和臨床試驗記錄，以確定可行的藥物標靶並預測化合物行為。機器學習演算法可以篩選數千種潛在分子，並根據預測的功效、毒性和生物利用度對它們進行排序，從而簡化臨床前篩檢階段。人工智慧生成模型甚至可以設計出滿足特定治療要求的新型分子結構。此外，人工智慧正在改進生物標記的選擇和檢驗，幫助研究人員更有效地將藥物與正確的患者群體配對。這些技術進步不僅加快了早期研發速度，也降低了昂貴的後期臨床試驗失敗的風險。自然語言處理工具正被用來分析科學文獻、專利和臨床資料庫，發掘先前被忽視的洞見。透過將真實世界證據與歷史數據結合，人工智慧可以增強預測模型，支持假設生成，並在開發過程中做出更明智的「通過/不通過」決策。最終，我們建立了一個更敏捷、數據主導的藥物發現模型，從而縮短上市時間並提高臨床成功率。人工智慧在藥物開發中的作用已不再局限於實驗階段。它正成為醫藥創新的重要工具，幫助企業更快、更有效率地為患者帶來新的治療方法。

人工智慧在臨床試驗、個人化醫療和法規遵循方面發揮什麼作用？

人工智慧正在對臨床試驗管理、個人化醫療和監管工作流程產生深遠的影響。這些領域傳統上充滿了複雜性、多變性和低效率。在臨床試驗中，人工智慧被用於最佳化患者招募，這是臨床試驗實施中最大的瓶頸之一。透過分析電子健康記錄、基因數據和健康的社會決定因素，人工智慧系統可以更快地識別出合格的患者，並預測他們堅持治療和產生反應的可能性。人工智慧還支援自適應試驗設計，其中通訊協定根據輸入資料即時修改，從而提高試驗效率和統計能力。在個人化醫療中，人工智慧對於破解每個患者的生物學獨特性並將其與標靶治療相匹配至關重要。演算法分析基因組序列、蛋白質表達，甚至微生物組圖譜，以預測藥物反應並最大限度地減少副作用，為更個人化的治療計劃鋪平道路。在監管業務中，人工智慧透過自動更新指南、發出安全警告和監控不同市場的標籤要求來幫助確保合規性。智慧型文件處理工具正被用於準備提交資料、識別差異並簡化與FDA和EMA等監管機構的互動。藥物安全檢測是另一個受益於人工智慧的領域，機器學習系統被用於檢測來自社群媒體、臨床記錄和上市後報告等不同資料來源的不利事件訊號。這些功能可以減少人工工作，並提高安全評估的準確性和及時性。透過改變臨床、個人化和監管格局，人工智慧不僅加速了從實驗室到患者的整個過程，還確保治療更安全、更有效，並更好地滿足個人需求。

製藥和生技公司如何將人工智慧融入經營模式和研發基礎設施？

為了在創新主導的環境中保持競爭力，製藥和生物技術公司正擴大將人工智慧納入其核心業務策略和研發基礎設施。大型製藥企業正在與人工智慧Start-Ups和高科技公司建立策略夥伴關係，共同開發用於靶點識別、化合物篩檢和測試最佳化的平台。這些聯盟提供了獲取專業知識和獨特資料集的途徑，從而顯著縮短了研發時間。許多公司也正在建立內部人工智慧卓越中心，聘請資料科學家、生物資訊學家和計算化學家，以整合各部門的人工智慧能力。雲端基礎平台和高效能運算正被用於處理基因組學、臨床研究和數位健康應用產生的大量數據。主導的平台正被用於投資組合的優先排序，幫助決策者根據預測分析來評估哪些資產應該推進或擱置。在製造業，人工智慧支援流程最佳化、品管和預測性維護，確保產品品質始終如一併降低營運成本。在銷售和行銷方面，人工智慧工具可以分析市場趨勢、處方模式和客戶回饋，從而為醫療服務提供者和患者制定個人化的互動策略。此外，人工智慧正在數位治療和伴隨診斷領域不斷拓展其作用，助力開發將傳統藥物與軟體主導的監測和行為干預相結合的綜合治療解決方案。轉向以人工智慧為中心的經營模式並非僅限於大型企業。新興生物科技公司從一開始就利用人工智慧來實現差異化、建立精實營運並吸引投資。隨著人工智慧的日趨成熟，它正成為製藥價值鏈各個階段的策略賦能者，培育創新、速度和精準的文化。

是什麼推動了人工智慧在全球製藥和生物技術市場的持續成長？

人工智慧在製藥和生物技術市場的成長是由不斷成長的醫療保健需求、不斷擴大的資料集、技術創新以及良好的監管和投資環境共同推動的。包括癌症、阿茲海默症和罕見遺傳疾病在內的慢性和複雜疾病的全球負擔迫切需要更快、更有效的治療方案。人工智慧可以透過加速藥物發現和提高治療精度來幫助滿足這一需求。電子健康記錄、基因組定序和穿戴式健康設備的廣泛應用導致了大量結構化和非結構化資料的積累，為人工智慧模型提供了動力。自然語言處理、機器學習和神經網路的技術進步使得能夠以以前難以想像的方式分析這些數據，從而獲得指南藥物開發、臨床決策和打入市場策略的見解。旨在促進生命科學領域人工智慧創新的政府舉措和官民合作關係也透過為研究和部署提供資金和政策支援來支持成長。專注於人工智慧的生物科技公司的創業投資持續激增，反映出人們對人工智慧賦能藥物開發的市場潛力充滿信心。精準醫療的興起和以患者為中心的醫療保健的推廣，進一步推動了對能夠實現個人化治療策略的人工智慧工具的需求。全球製藥公司也面臨著降低成本和提高研發效率的壓力，這使得人工智慧成為持續創新的一個有希望的解決方案。隨著成功案例的增多，包括人工智慧發現的候選藥物進入臨床試驗，生命科學領域對人工智慧的信任和採用持續成長。這些因素共同推動製藥和生物技術領域人工智慧市場的強勁持續擴張，標誌著一個數據主導、技術賦能的醫療保健創新新時代的到來。

部分

應用程式（藥物發現和開發應用程式、臨床試驗和最佳化應用程式、預測性維護和品管應用程式、藥物發現目標識別應用程式、疾病診斷和預後應用程式和其他應用程式）、最終用戶（製藥和生物技術公司、學術和研究機構和其他最終用戶）

受訪公司範例

  • AbbVie
  • AstraZeneca
  • Biogen
  • Boehringer Ingelheim
  • CureMetrix
  • Exscientia
  • Flatiron Health
  • GSK
  • IBM Watson Health
  • Insilico Medicine
  • Johnson & Johnson
  • Lilly
  • Medtronic
  • Merck & Co.
  • NVIDIA
  • PathAI
  • Recursion Pharmaceuticals
  • Sanofi
  • Tempus
  • Zymergen

人工智慧整合

全球產業分析師利用可操作的專家內容和人工智慧工具改變市場和競爭情報。

Global Industry Analysts 沒有遵循典型的 LLM 或特定於行業的 SLM查詢，而是建立了一個從世界各地的專家收集的內容庫，其中包括影片錄像、BLOG、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地和進出口（成品和原始設備製造商）情況預測其競爭地位的變化。這種複雜而多面的市場動態預計將以多種方式影響競爭對手，包括銷貨成本(COGS) 上升、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲國家
  • 亞太地區
  • 其他地區

第4章 競賽

簡介目錄
Product Code: MCP38499

Global Artificial Intelligence (AI) in Pharma and Biotech Market to Reach US$9.0 Billion by 2030

The global market for Artificial Intelligence (AI) in Pharma and Biotech estimated at US$3.1 Billion in the year 2024, is expected to reach US$9.0 Billion by 2030, growing at a CAGR of 19.2% over the analysis period 2024-2030. Drug Discovery & Development Application, one of the segments analyzed in the report, is expected to record a 17.9% CAGR and reach US$2.6 Billion by the end of the analysis period. Growth in the Clinical Trials & Optimization Application segment is estimated at 17.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$822.8 Million While China is Forecast to Grow at 18.3% CAGR

The Artificial Intelligence (AI) in Pharma and Biotech market in the U.S. is estimated at US$822.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2030 trailing a CAGR of 18.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 17.5% and 16.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.3% CAGR.

Global Artificial Intelligence (AI) in Pharma and Biotech Market - Key Trends & Drivers Summarized

How Is AI Revolutionizing the Drug Discovery and Development Lifecycle?

Artificial Intelligence is dramatically reshaping the pharmaceutical and biotechnology industries by accelerating and optimizing the entire drug discovery and development process. Traditional drug development is an expensive, time-consuming endeavor that often takes over a decade and costs billions of dollars to bring a single new drug to market. AI is changing this paradigm by enabling the rapid analysis of massive datasets, such as genomics, proteomics, and clinical trial records, to identify viable drug targets and predict the behavior of chemical compounds. Machine learning algorithms can sift through thousands of potential molecules and rank them based on predicted efficacy, toxicity, and bioavailability, thereby streamlining the preclinical screening phase. Generative AI models are even capable of designing novel molecular structures that meet specified therapeutic requirements. Moreover, AI is improving the selection and validation of biomarkers, helping researchers match drugs to the right patient populations more effectively. These innovations not only speed up early-stage R&D but also reduce the risk of failure in costly late-stage trials. Natural language processing tools are being used to analyze scientific literature, patents, and clinical databases to uncover previously overlooked insights. By integrating real-world evidence and historical data, AI enhances predictive modeling, supports hypothesis generation, and allows for more informed go/no-go decisions during development. The net result is a more agile and data-driven drug discovery model, reducing time to market and improving the chances of clinical success. AI’s role in drug development is no longer experimental; it is becoming an essential tool for pharmaceutical innovation, helping companies bring new treatments to patients faster and more efficiently.

What Role Is AI Playing in Clinical Trials, Personalized Medicine, and Regulatory Compliance?

AI is making a profound impact on clinical trial management, personalized medicine, and regulatory workflows, areas that are traditionally laden with complexity, variability, and inefficiency. In clinical trials, AI is being deployed to optimize patient recruitment, one of the biggest bottlenecks in trial execution. By analyzing electronic health records, genetic data, and social determinants of health, AI systems can identify eligible patients faster and predict their likelihood of adherence and response to treatment. AI also supports adaptive trial designs, where protocols are modified in real-time based on incoming data, improving trial efficiency and statistical power. For personalized medicine, AI is crucial in deciphering the biological uniqueness of individual patients and matching them with targeted therapies. Algorithms analyze genomic sequences, protein expressions, and even microbiome profiles to predict drug response and minimize adverse effects, paving the way for more customized treatment plans. In regulatory affairs, AI helps ensure compliance by automating the monitoring of guideline updates, safety alerts, and labeling requirements across different markets. Intelligent document processing tools are being used to prepare submissions, identify inconsistencies, and streamline interactions with regulatory agencies such as the FDA and EMA. Pharmacovigilance is another area benefiting from AI, where machine learning systems are used to detect adverse event signals from disparate data sources, including social media, clinical notes, and post-marketing reports. These capabilities reduce manual workload and enhance the accuracy and timeliness of safety assessments. By transforming the clinical, personalized, and regulatory landscape, AI is not only accelerating the path from lab to patient but also ensuring that treatments are safer, more effective, and more tailored to individual needs.

How Are Pharma and Biotech Companies Integrating AI into Their Business Models and R&D Infrastructure?

Pharma and biotech companies are increasingly embedding AI into their core business strategies and R&D infrastructure to stay competitive in an innovation-driven landscape. Large pharmaceutical firms are forming strategic partnerships with AI startups and tech companies to co-develop platforms for target identification, compound screening, and trial optimization. These collaborations enable access to specialized expertise and proprietary datasets that can significantly accelerate R&D timelines. Many companies are also establishing internal AI centers of excellence, hiring data scientists, bioinformaticians, and computational chemists to integrate AI capabilities across departments. Cloud-based platforms and high-performance computing are being adopted to handle the massive volume of data generated from genomics, clinical studies, and digital health applications. AI-driven platforms are being used for portfolio prioritization, helping decision-makers assess which assets to advance or shelve based on predictive analytics. On the manufacturing side, AI supports process optimization, quality control, and predictive maintenance, ensuring consistent product quality and reducing operational costs. In sales and marketing, AI tools analyze market trends, prescription patterns, and customer feedback to develop personalized engagement strategies for healthcare providers and patients. Additionally, AI is playing a growing role in digital therapeutics and companion diagnostics, enabling the development of integrated treatment solutions that combine traditional drugs with software-driven monitoring and behavioral interventions. This shift toward AI-centric business models is not limited to large enterprises. Emerging biotech firms are using AI from day one to differentiate themselves, build leaner operations, and attract investment. As AI matures, it is becoming a strategic enabler that cuts across every phase of the pharmaceutical value chain, fostering a culture of innovation, speed, and precision.

What Is Driving the Sustained Global Growth of AI in the Pharma and Biotech Market?

The growth in the artificial intelligence in pharma and biotech market is driven by a combination of rising healthcare demands, expanding datasets, technological innovation, and a favorable regulatory and investment environment. The global burden of chronic and complex diseases such as cancer, Alzheimer’s, and rare genetic disorders is creating an urgent need for faster and more effective therapeutic solutions. AI helps meet this need by accelerating drug discovery and improving treatment precision. The widespread adoption of electronic health records, genomic sequencing, and wearable health devices has created a vast and growing pool of structured and unstructured data that fuels AI models. Technological advancements in natural language processing, machine learning, and neural networks have made it possible to analyze this data in ways that were previously unimaginable, unlocking insights that guide drug development, clinical decision-making, and market access strategies. Government initiatives and public-private partnerships aimed at fostering AI innovation in life sciences are also supporting growth, providing funding and policy support for research and deployment. Venture capital investment in AI-focused biotech startups continues to surge, reflecting strong confidence in the market potential of AI-driven drug development. The emergence of precision medicine and the push for patient-centric healthcare are further reinforcing the demand for AI tools that enable personalized treatment strategies. Global pharmaceutical companies are also under pressure to reduce costs and improve R&D efficiency, making AI a compelling solution for sustaining innovation. As more success stories emerge, such as AI-discovered drug candidates entering clinical trials, the credibility and adoption of AI in the life sciences continue to grow. These factors are collectively fueling a robust and sustained expansion of the AI market within the pharma and biotech sectors, signaling a new era of data-driven, technology-enabled healthcare innovation.

SCOPE OF STUDY:

The report analyzes the Artificial Intelligence (AI) in Pharma and Biotech market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Application (Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application, Other Applications); End-User (Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 36 Featured) -

  • AbbVie
  • AstraZeneca
  • Biogen
  • Boehringer Ingelheim
  • CureMetrix
  • Exscientia
  • Flatiron Health
  • GSK
  • IBM Watson Health
  • Insilico Medicine
  • Johnson & Johnson
  • Lilly
  • Medtronic
  • Merck & Co.
  • NVIDIA
  • PathAI
  • Recursion Pharmaceuticals
  • Sanofi
  • Tempus
  • Zymergen

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Artificial Intelligence (AI) in Pharma and Biotech - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising R&D Costs and Long Development Cycles Spur Demand for AI-Driven Drug Discovery and Optimization Platforms
    • Here's How Generative AI Strengthens the Business Case for De Novo Molecule Design and Target Prediction
    • Integration of AI with Omics and Real-World Data Throws the Spotlight on Precision Medicine and Biomarker Discovery
    • Here's the Story: Natural Language Processing Enables Deep Mining of Scientific Literature and Biomedical Databases
    • AI-Powered Predictive Modeling Enhances Compound Screening, Toxicity Assessment, and Lead Candidate Prioritization
    • Digital Twins and Simulation Technologies Expand the Addressable Market for In Silico Testing and Virtual Clinical Trials
    • AI in Bioprocess Optimization and Manufacturing Improves Yield, Scalability, and Quality Control in Biotech Operations
    • Growing Focus on Rare Diseases and Orphan Drug Development Supports Use of AI to Identify Small, High-Impact Patient Populations
    • Here's the Story: Regulatory Acceptance of AI in Drug Development Workflows Drives Frameworks for Validation and Compliance
    • Integration of AI in Pharmacovigilance Enhances Post-Marketing Surveillance and Signal Detection Capabilities
    • Expansion of AI-Powered Platforms in Vaccine Development Demonstrates Potential in Rapid Response to Emerging Pathogens
    • Here's How Cloud Infrastructure and Data Interoperability Accelerate the Scalability of AI Tools Across the Drug Development Lifecycle
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Artificial Intelligence (AI) in Pharma and Biotech Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Drug Discovery & Development Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Drug Discovery & Development Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Clinical Trials & Optimization Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Clinical Trials & Optimization Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Predictive Maintenance & Quality Control Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Predictive Maintenance & Quality Control Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Drug Target Identification Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Drug Target Identification Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Disease Diagnosis & Prognosis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Disease Diagnosis & Prognosis Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Pharma & Biotech Companies End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Academic & Contract Research Organizations End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Academic & Contract Research Organizations End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Artificial Intelligence (AI) in Pharma and Biotech Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 22: USA Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 23: USA 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
    • TABLE 24: USA Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 25: USA 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
    • TABLE 28: Canada Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: Canada 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030
  • JAPAN
    • Artificial Intelligence (AI) in Pharma and Biotech Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 30: Japan Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Japan 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030
  • CHINA
    • Artificial Intelligence (AI) in Pharma and Biotech Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 34: China Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: China 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
    • TABLE 36: China Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: China 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030
  • EUROPE
    • Artificial Intelligence (AI) in Pharma and Biotech Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: Europe 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 40: Europe Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Europe 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
    • TABLE 42: Europe Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Europe 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030
  • FRANCE
    • Artificial Intelligence (AI) in Pharma and Biotech Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 44: France Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: France 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
    • TABLE 46: France Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: France 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030
  • GERMANY
    • Artificial Intelligence (AI) in Pharma and Biotech Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 48: Germany Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Germany 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
    • TABLE 50: Germany Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Germany 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030
  • ITALY
    • TABLE 52: Italy Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Italy 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
    • TABLE 54: Italy Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Italy 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030
  • UNITED KINGDOM
    • Artificial Intelligence (AI) in Pharma and Biotech Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 56: UK Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: UK 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
    • TABLE 58: UK Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: UK 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 60: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Rest of Europe 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
    • TABLE 62: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Rest of Europe 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Artificial Intelligence (AI) in Pharma and Biotech Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 64: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Asia-Pacific 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
    • TABLE 66: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Asia-Pacific 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 68: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Rest of World 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
    • TABLE 70: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Rest of World 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030

IV. COMPETITION